文献速递肾小球疾病

在IgA肾病中应如何测量和解读肾小球炎症,以及最佳抗炎策略是什么

How should we measure and interpret glomerular inflammation and what is the best anti-inflammatory approach in IgA nephropathy?
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本文综述IgA肾病的发病机制涉及肠黏膜-肾脏相互作用、半乳糖缺陷型IgA1及免疫复合物形成,先天与适应性免疫均参与炎症级联放大。广谱免疫抑制(全身或肠道局部糖皮质激素、吗替麦考酚酯)可减少蛋白尿但伴不良反应风险,补体抑制及BAFF和/或APRIL抑制剂等靶向治疗正在评估中。目前测量肾小球炎症程度和预测治疗反应的能力仍有限,IgA国际风险预测工具仍是预测5年肾脏结局的金标准,亟需经验证反映炎症或疾病活动度的生物标志物以支持个体化治疗。

要点

  • IgA肾病发病涉及肠黏膜-肾脏轴、半乳糖缺陷型IgA1及抗聚糖抗体免疫复合物形成。
  • 广谱免疫抑制(全身或肠道局部糖皮质激素、吗替麦考酚酯)可减少蛋白尿但伴不良反应风险。
  • 补体抑制及BAFF和/或APRIL抑制剂等靶向治疗显示前景,正在评估中。

核心结论

  • 改变IgA肾病疾病轨迹需要针对其潜在炎症过程的治疗,靶向特定通路的治疗显示前景并正在评估中。
  • 测量肾小球炎症程度和预测治疗反应的能力仍有限,亟需经验证反映炎症或疾病活动度的生物标志物以促进个体化治疗策略并改善长期结局。

研究设计与样本

  • 综述,围绕IgA肾病的肾小球炎症测量与抗炎治疗策略进行论述。

主要发现

  • IgA肾病发病机制复杂,以肠黏膜-肾脏相互作用导致半乳糖缺陷型IgA1产生并与抗聚糖抗体形成免疫复合物为特征。
  • 先天与适应性免疫系统均参与修饰或放大导致疾病进展的炎症级联。
  • 广谱免疫抑制包括全身或肠道黏膜局部递送糖皮质激素及吗替麦考酚酯,已显示减少蛋白尿的疗效,但受不良反应风险限制。
  • 补体抑制及BAFF和/或APRIL抑制剂等针对特定通路的靶向治疗显示前景,正在评估中。
  • IgA国际风险预测工具仍是预测最长5年肾脏结局的金标准,依据蛋白尿、估算肾小球滤过率及MEST-C组织学评分等临床标准。

关键数值与推荐

  • IgA国际风险预测工具为预测最长5年肾脏结局的金标准,依据蛋白尿、估算肾小球滤过率及MEST-C评分等临床与组织学标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 测量肾小球炎症程度和预测治疗反应的能力仍有限。
  • 亟需经验证反映炎症程度或IgA肾病疾病活动度的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. The pathogenesis of IgAN is complex, characterized by gut mucosa-kidney interactions that lead to the production of galactose-deficient IgA1 and formation of immune complexes with antiglycan antibodies. Both arms of the adaptive and innate immune system are implicated in modifying or amplifying inflammatory cascades that lead to disease progression. Thus, altering the disease trajectory in IgAN requires therapies that target these underlying inflammatory processes. Broad immunosuppression, including systemic or locally gut mucosa-delivered corticosteroids and mycophenolate mofetil, have demonstrated efficacy in reducing proteinuria, although these are tempered by the risk of adverse effects. More recently, targeted treatment approaches at specific pathways, including complement inhibition and BAFF and/or APRIL inhibitors, have demonstrated promise and are under evaluation. Our ability to measure the degree of glomerular inflammation and predict response to treatment remains limited. To date, the IgA International Risk Prediction Tool remains the gold standard for the prediction of up to 5-year kidney outcomes guided by clinical criteria including proteinuria, estimated glomerular filtration rate and histologic criteria through the MEST-C score. With multiple potential emerging treatments, there is a need for validated biomarkers that reflect the degree of inflammation or IgAN disease activity that may facilitate personalized treatment strategies and improve long-term outcomes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Yau K, Reich HN. How should we measure and interpret glomerular inflammation and what is the best anti-inflammatory approach in IgA nephropathy? Nephrol Dial Transplant. 2026. PMID: 40795024. doi:10.1093/ndt/gfaf135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。